Biodesix (BDSX) Fundamental Analysis: Revenue, Earnings & Valuation

0.79 / 10

Underperform

Fundamental rating is Underperform with a 0.8/10 score. Cash‑to‑market and ROE are severely negative, dragging performance. Interest coverage and Asset‑MV provide modest support, but overall fundamentals remain weak, urging prudence.

Analysis Checks(4/10)

Net assets per share (growth rate compared to beginning of year %)

Value-308.16

Score0/3

Weight19.62%

1M Return-6.98%

Annualized return on equity (%)

Value-383.09

Score0/3

Weight18.34%

1M Return-6.47%

Quick ratio

Value2.28

Score0/3

Weight10.94%

1M Return-3.43%

Fixed assets turnover ratio

Value3.08

Score3/3

Weight-7.70%

1M Return2.16%

Long-term debt to working capital ratio (%)

Value4.81

Score0/3

Weight15.66%

1M Return-4.85%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight9.31%

1M Return-3.03%

Asset-MV

Value-0.49

Score2/3

Weight4.01%

1M Return-1.31%

ROE (%)

Value-383.09

Score0/3

Weight18.34%

1M Return-6.47%

Current assets / Total assets (%)

Value37.17

Score3/3

Weight-5.28%

1M Return1.48%

Cash-MV

Value-3.76

Score0/3

Weight16.76%

1M Return-8.60%

Is BDSX undervalued or overvalued?

BDSX scores 0.79/10 on fundamentals and holds a Premium valuation at present. Backed by its -383.09% ROE, -39.85% net margin, -4.21 P/E ratio, -60.27 P/B ratio, and 29.67% earnings growth, these metrics solidify its Underperform investment rating.